Portfolio of Genomics Stocks
Genomics includes agrigenomics, bacterial genomics, bioinformatics, cancer genomics, diagnostics, drug discovery, equipment, pharmacogenomics and research.
Here is a table of 11 genomics stocks.
| 11 Genomics Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| Agilent Technologies | A | |
| Alnylam Pharmaceuticals | ALNY | |
| CRISPR Therapeutics | CRSP | |
| Editas Medicine | EDIT | |
| Exact Sciences | EXAS | |
| Illumina | ILMN | |
| Ionis Pharmaceuticals | IONS | |
| Myriad Genetics | MYGN | |
| QIAGEN N.V. | QGEN | |
| Sangamo Therapeutics | SGMO | |
| Spark Therapeutics | ONCE | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Genomics Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.The 7 stocks included in the portfolio computations are: A, ALNY, EXAS, ILMN, MYGN, QGEN and SGMO. The current value of the portfolio assumes that $1,428.57 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 4 stocks excluded from the portfolio computations because of insufficient price data are: CRSP, EDIT, IONS and ONCE.
The current value of a $10,000 investment is $106,628. The percent return is 966.28%. The annualized return is 26.70%.
| Return Summary for Genomics Stocks | |
|---|---|
| Start Date | Aug-31-2009 |
| Start Investment | $10,000.00 |
| End Date | Aug-23-2019 |
| Current Value of Investment | $106,627.60 |
| Total Return | 966.28% |
| Annualized Return | 26.70% |
| Min Date | Oct-30-2009 |
| Min Price | $9,076.11 |
| Max Date | Jun-28-2019 |
| Max Price | $111,436.92 |
| # Values | 121 |
| Number Returns | 7,260 |
| Number Profitable Returns | 6,606 |
| Percent Profitable Returns | 90.99% |
| Number Unprofitable Returns | 654 |
| Percent Unprofitable Returns | 9.01% |
| Profitable to Unprofitable Returns Ratio | 10.10 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.
Related Portfolios
Portfolio of Gene Editing (CRISPR) Stocks
Portfolio of Genetic Testing Stocks
Portfolio of Stem Cell Stocks